Australian pharmaceutical company Phebra is going green as it announces the energy efficiency program which will be implemented at its sterile manufacturing plant in Sydney.
In a media release Phebra said that the installation of new lighting, cooling and energy management systems throughout the Lane Cove West facility will dramatically reduce its carbon footprint, with an estimated saving of 328 tonnes.
New LED light fittings will be installed in the warehouse, which will reduce current energy consumption by 70 percent. 20 percent will also be saved from the ‘Smartcool’ air conditioning system.
Sydney firm Green Energy Technical Services (GETS) is tasked with Stage One of the project which includes new T5 and emergency LED light fittings in the car park, offices and throughout the building and sensor energy management system to ensure that lighting is only used when necessary.
The company will also install a “green clock” which will be displayed in the foyer to show the amount of CO2 emissions saved everyday, with the data being streamed live on the Phebra and GETS websites. The Phebra staff will also be receiving training from GETS on ways to reduce energy consumption.
“The new plant has provided Phebra with a wonderful opportunity to firstly measure the company’s energy usage and then look at innovative ways of reducing our emissions and improving cost efficiencies across the business,” said Dr. Mal Eutick, Phebra Chief Executive Officer.
Dr. Eutick said the energy efficiency program is part of the company’s ongoing commitment to cut down on energy and emissions in the plant’s everyday manufacturing and operations.
“We have already been encouraged by the estimated 328 tonnes of carbon that Phebra will save each year and believe the new system will lay the foundation for sustainable manufacturing processes for us well into the future.”
“Upon the completion of the current program, we will be looking at the installation of solar panelling on the roof of the plant as well as undertaking a water conservation audit to identify ways Phebra can save on water,” Dr Eutick added.
Privately-owned Phebra specialises in the development, manufacture, marketing and distribution of highly specialised and innovative medicines for the hospital sector. Marketing a range of products in therapeutic areas including anti-infectives, cardiovascular and respiratory disease, central nervous system, oncology and pain and vitamins.
The company also partners with major medical institutions Sydney, Melbourne and Newcastle and will most likely benefit from the support of the Gillard Government, which has announced clinical trials as part of the $1 billion Plan for Australian Jobs.